Back to Agenda
Critical Appraisal of Artificial Intelligence Solutions for Pharmacovigilance
Session Chair(s)
Jim Barrett, PhD, MSc
Senior Data Scientist
Uppsala Monitoring Centre (UMC), Sweden
Artificial intelligence solutions may support and enhance human decision-making and information processing throughout pharmacovigilance. This session aims to outline best practices and potential pitfalls in their use.
Learning Objective : Recognize key challenges in assessing artificial intelligence solutions and interpreting evaluations of their performance; Describe some best practices for critical appraisal of artificial intelligence solutions; Identify the need for consideration of human computer interactions.
Speaker(s)
MHRA Update
Phil Tregunno
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Deputy Director - Patient Safety Monitoring
FDA Update
Monica Munoz, PharmD, PhD
FDA, United States
Division Director, Division of Pharmacovigilance-I, OSE, CDER
Industry Update
Andrew Bate, PhD, MA
GlaxoSmithKline, United Kingdom
Vice President, Head of Safety Innovation and Analytics
Have an account?